Skip to Main Content
Quantitative Pharmacology and Individualized Therapy Strategies in Development of Therapeutic Proteins for Immune-Mediated Inflammatory Diseases
book

Quantitative Pharmacology and Individualized Therapy Strategies in Development of Therapeutic Proteins for Immune-Mediated Inflammatory Diseases

by Honghui Zhou, Diane R. Mould
March 2019
Intermediate to advanced content levelIntermediate to advanced
496 pages
15h
English
Wiley
Content preview from Quantitative Pharmacology and Individualized Therapy Strategies in Development of Therapeutic Proteins for Immune-Mediated Inflammatory Diseases

4 Application of Minimal Anticipated Biological Effect Level (MABEL) in Human Starting Dose Selection for Immunomodulatory Protein Therapeutics – Principles and Case Studies

Haiqing Wang1, Zheng Yang1 and Rong Shi2

1Bristol‐Myers Squibb Co., Department of Metabolism and Pharmacokinetics, Pharmaceutical Candidate Optimization, 3551 Lawrenceville Princeton, Lawrence Township, NJ, 08648, USA

2Bristol‐Myers Squibb Co., Department of Clinical Pharmacology and Pharmacometrics, 3551 Lawrenceville Princeton, Lawrence Township, NJ, 08648, USA

4.1 Introduction

Immunomodulatory protein therapeutics (IMPTs) are designed to interact with one or more components of the immune system to either enhance or suppress immune responses. These protein therapeutics have revolutionized the treatment of cancer and immune‐related diseases in the past two decades. One of the most notable examples is the immune checkpoint inhibitors, such as anti‐cytotoxic T‐lymphocyte‐associated protein 4 (CTLA‐4, Yervoy®) and anti‐programmed cell death protein 1 (PD‐1) (Opdivo® and Keytruda®) monoclonal antibodies (mAbs), which have demonstrated remarkable anti‐tumor efficacy by effectively enhancing patient immune responses against cancer cells [1]. Likewise, immune suppressive therapeutic proteins such as anti‐tumor necrosis factor α (TNFα) antibody (e.g. Humira®) and CTLA‐4 Fc fusion protein (Oriencia®) have also improved the treatment of various inflammatory and autoimmune diseases [2].

A key challenge in ...

Become an O’Reilly member and get unlimited access to this title plus top books and audiobooks from O’Reilly and nearly 200 top publishers, thousands of courses curated by job role, 150+ live events each month,
and much more.
Start your free trial

You might also like

Applied Computing in Medicine and Health

Applied Computing in Medicine and Health

Dhiya Al-Jumeily, Abir Hussain, Conor Mallucci, Carol Oliver
Informatics for Health Professionals

Informatics for Health Professionals

Kathleen Mastrian, Dee McGonigle
Nanostructures for Novel Therapy

Nanostructures for Novel Therapy

Denisa Ficai, Alexandru Mihai Grumezescu

Publisher Resources

ISBN: 9781119289197Purchase book